Hyderabad Engineers Patent a Microwave Antenna to Screen for Breast and Skin Cancer
A VNR Vignana Jyothi Institute team led by Professor K. Vidya Sagar has patented a microstrip antenna that flags tumour-like tissue by measuring reflected microwave signals — a non-invasive, radiation-free concept still years from clinical use.
A Personal Loss Behind the Patent
K. Vidya Sagar, a professor at VNR Vignana Jyothi Institute of Engineering and Technology (VNR-VJIET) in Hyderabad, has been granted a patent for a microwave antenna designed to flag abnormal or cancerous tissue in the breast and skin without cutting into the body. Sagar has said the work is personal: he lost his mother to a rare cancer, and spent roughly six months consulting oncologists and medical professionals while developing the concept, trying to understand where existing detection methods fall short for patients in cost- or access-constrained settings.
The patent itself was reported on September 23 and September 25, 2026, across two separate outlets, giving a consistent account of a technology that is real — granted, not merely filed — but still firmly in the pre-clinical stage.
How the Antenna Works
The core idea is a microstrip patch antenna, a small, flat, relatively cheap-to-manufacture radiating element that's placed close to the tissue being examined. The device transmits low-power, non-ionizing electromagnetic energy at microwave frequencies toward the tissue and then measures what bounces back. Healthy tissue and abnormal or malignant tissue interact differently with that energy because of differences in water content, cell density and other dielectric properties — differences that show up as a measurable shift in what engineers call "return loss," the ratio of reflected to transmitted signal power.
In practice, that means the system doesn't image tissue the way an MRI or mammogram does. It compares a return-loss signature against an expected baseline and flags a deviation. That's a simpler, cheaper measurement problem than full imaging, which is the appeal — and also the limitation, since a shift in return loss can point to an abnormality without necessarily characterising what kind.
The advantage over existing options is straightforward: no ionizing radiation, unlike X-ray mammography, and potentially far lower equipment and operating cost than MRI or PET-based screening. Both of those matter directly for screening accessibility in India, where mammography infrastructure remains concentrated in urban centres and PET scans are expensive enough to be impractical for routine screening.
What Stage This Is At
It's important to be precise about where this technology actually sits, because the coverage has been careful to flag the same caveat: the work so far is limited to computer simulations. The antenna design has been validated through electromagnetic modelling software, not through physical prototypes tested on tissue samples, artificial phantoms, or patients. Sagar's own account, per the reporting, lays out the next steps as manufacturing physical antenna units, testing them against artificial tissue models in a lab setting, and only then moving toward clinical studies.
That sequencing is standard for medical-device research and is worth stating plainly: a granted patent covers the novelty of the antenna design and detection concept, not clinical efficacy or regulatory approval. Getting from a validated simulation to a device cleared for patient use typically takes years and requires clearing India's Central Drugs Standard Control Organisation (CDSCO) medical-device pathway, along with the underlying clinical trial data that pathway demands.
Why Microwave Imaging Matters
Sagar's work fits into a broader, internationally active research area. Microwave-based breast tissue characterisation has been studied for over two decades globally, with several prototype systems — including ones that have reached pilot clinical trials abroad — built around similar physical principles: non-ionizing radiation, low cost relative to MRI, and portability that could in principle support screening outside major hospital settings. None of these approaches has yet displaced mammography as a primary screening tool anywhere, largely because distinguishing benign from malignant abnormalities reliably, at the resolution regulators require, has proven harder than the initial physics suggested.
What makes an Indian academic effort in this space notable isn't novelty of the underlying physics — return-loss-based tissue characterisation is a known technique — but the framing around cost and access. If a working version eventually clears lab and clinical validation, the appeal for Indian healthcare planners would be a low-cost, radiation-free adjunct screening tool that could be deployed more widely than mammography infrastructure currently allows, particularly for cancer types like skin lesions where the technology's simpler geometry might reach usable accuracy faster than breast tissue, which is more heterogeneous and harder to characterise with a single-antenna measurement.
The Road Ahead
VNR-VJIET has not disclosed external funding for the next phases, and neither report names a specific timeline for lab-based testing or eventual human trials. That absence of a committed roadmap is itself informative: this remains an academic proof-of-concept at the patent stage, not a funded medtech venture with a defined path to market. Readers should treat the granted patent as validation of an idea's originality, not as evidence the device works reliably on real tissue — that evidence doesn't exist yet, and won't for at least the next few years, if the technology advances at the pace Sagar has described.